FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311751475> ?p ?o ?g. }

• W4311751475 abstract "Abstract Background To cope with the SARS-CoV-2 pandemic, several treatments were studied and out of these, monoclonal antibodies (MAbs) have shown efficacy to prevent the development of pneumonia after the infection Methods We conducted a retrospective, single-center study including patients with SARS-CoV-2 infection, treated with MAbs (bamlanivimab/etesevimab (B/E), casirivimab/imdevimab (C/I) or sotrovimab (S)) from March 2021 to February 2022 Results We included 504 patients with a median age of 62 years (IQR 49-72), 51% were males and 66% had completed the vaccination schedule according to the current Italian regulations. The most frequent eligibility criteria are summarized in figure 1. As for MAbs combination, patients were treated with B/E (54%), followed by C/I (30%) and S (16%). Outcomes are shown in Table 1. Nasopharyngeal swab (NPS) negativization time had a positive correlation with patients’ age (r=0.16; p=0.001), C-reactive protein (CRP) (r=0.26; p&lt; 0.001) and creatinine values (r=0.22; p&lt; 0.001) assessed at baseline (infusion day). Time to NPS negativization was 6.9 (95% C.I. [4.5-9.2]) days shorter for vaccinated compared to unvaccinated patients (p&lt; 0.001). Patients treated with C/I had a negative NPS on average 4.5 (95% C.I.= [1.8-7.3] days earlier than patients treated with B/E; patients who received S reached negativization 6.0 (95% C.I.= [2.2, 9.9]) days earlier than those treated with B/E (p=0.004). Patients with positive outcome had a negative NPS on average 14.3 (95% C.I.= [6.8, 23.1)], 25.5 (95% C.I.= [18.9, 33.4] and 68.3 (95% C.I.= [47.7, 90.2]) days earlier than patients who needed hospitalization and patients who died (p&lt; 0.001, p&lt; 0.001, respectively). Unvaccinated patients had a higher rate of oxygen support need compared to vaccinated ones (p=0.006). Patients with worse outcomes were significantly older and had higher values of CRP and creatinine at baseline (p=0.04, p&lt; 0.001, p&lt; 0.001, respectively) Percentage of eligibility criteria of our patients The majority of patients had more than one criterion Clinical outcome of our patients Nasopharyngeal swab was repeated weekly, until negative Conclusion MAbs reduce the risk of hospitalization in fragile patients. Vaccinated patients had shorter time of NPS negativization and lower probability of hospitalization. Older age, higher CRP and creatinine values assessed at baseline, correlated with worse outcomes. S was the most effective treatment amongst MAbs used in our study Disclosures All Authors: No reported disclosures." @default.
• W4311751475 created "2022-12-28" @default.
• W4311751475 creator A5001697007 @default.
• W4311751475 creator A5005663997 @default.
• W4311751475 creator A5020412439 @default.
• W4311751475 creator A5035607581 @default.
• W4311751475 creator A5040785751 @default.
• W4311751475 creator A5057710917 @default.
• W4311751475 creator A5060934194 @default.
• W4311751475 creator A5064623739 @default.
• W4311751475 creator A5076639211 @default.
• W4311751475 creator A5082536585 @default.
• W4311751475 creator A5084522868 @default.
• W4311751475 creator A5088510590 @default.
• W4311751475 date "2022-12-01" @default.
• W4311751475 modified "2023-09-30" @default.
• W4311751475 title "280. Monoclonal Antibodies Against SARS-CoV-2 in Fragile Outpatients: Clinical and Laboratory Risk Factors and Protective Role of Vaccination" @default.
• W4311751475 doi "https://doi.org/10.1093/ofid/ofac492.358" @default.
• W4311751475 hasPublicationYear "2022" @default.
• W4311751475 type Work @default.
• W4311751475 citedByCount "0" @default.
• W4311751475 crossrefType "journal-article" @default.
• W4311751475 hasAuthorship W4311751475A5001697007 @default.
• W4311751475 hasAuthorship W4311751475A5005663997 @default.
• W4311751475 hasAuthorship W4311751475A5020412439 @default.
• W4311751475 hasAuthorship W4311751475A5035607581 @default.
• W4311751475 hasAuthorship W4311751475A5040785751 @default.
• W4311751475 hasAuthorship W4311751475A5057710917 @default.
• W4311751475 hasAuthorship W4311751475A5060934194 @default.
• W4311751475 hasAuthorship W4311751475A5064623739 @default.
• W4311751475 hasAuthorship W4311751475A5076639211 @default.
• W4311751475 hasAuthorship W4311751475A5082536585 @default.
• W4311751475 hasAuthorship W4311751475A5084522868 @default.
• W4311751475 hasAuthorship W4311751475A5088510590 @default.
• W4311751475 hasBestOaLocation W43117514751 @default.
• W4311751475 hasConcept C126322002 @default.
• W4311751475 hasConcept C141071460 @default.
• W4311751475 hasConcept C167135981 @default.
• W4311751475 hasConcept C203014093 @default.
• W4311751475 hasConcept C22070199 @default.
• W4311751475 hasConcept C2777914695 @default.
• W4311751475 hasConcept C2779134260 @default.
• W4311751475 hasConcept C2780306776 @default.
• W4311751475 hasConcept C3008058167 @default.
• W4311751475 hasConcept C524204448 @default.
• W4311751475 hasConcept C71924100 @default.
• W4311751475 hasConcept C90924648 @default.
• W4311751475 hasConceptScore W4311751475C126322002 @default.
• W4311751475 hasConceptScore W4311751475C141071460 @default.
• W4311751475 hasConceptScore W4311751475C167135981 @default.
• W4311751475 hasConceptScore W4311751475C203014093 @default.
• W4311751475 hasConceptScore W4311751475C22070199 @default.
• W4311751475 hasConceptScore W4311751475C2777914695 @default.
• W4311751475 hasConceptScore W4311751475C2779134260 @default.
• W4311751475 hasConceptScore W4311751475C2780306776 @default.
• W4311751475 hasConceptScore W4311751475C3008058167 @default.
• W4311751475 hasConceptScore W4311751475C524204448 @default.
• W4311751475 hasConceptScore W4311751475C71924100 @default.
• W4311751475 hasConceptScore W4311751475C90924648 @default.
• W4311751475 hasIssue "Supplement_2" @default.
• W4311751475 hasLocation W43117514751 @default.
• W4311751475 hasLocation W43117514752 @default.
• W4311751475 hasOpenAccess W4311751475 @default.
• W4311751475 hasPrimaryLocation W43117514751 @default.
• W4311751475 hasRelatedWork W113810927 @default.
• W4311751475 hasRelatedWork W1586374228 @default.
• W4311751475 hasRelatedWork W2003938723 @default.
• W4311751475 hasRelatedWork W2047967234 @default.
• W4311751475 hasRelatedWork W2118496982 @default.
• W4311751475 hasRelatedWork W2364998975 @default.
• W4311751475 hasRelatedWork W2369162477 @default.
• W4311751475 hasRelatedWork W2439875401 @default.
• W4311751475 hasRelatedWork W4238867864 @default.
• W4311751475 hasRelatedWork W2525756941 @default.
• W4311751475 hasVolume "9" @default.
• W4311751475 isParatext "false" @default.
• W4311751475 isRetracted "false" @default.
• W4311751475 workType "article" @default.